Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis

Ostuzzi, Giovanni; Bertolini, Federico; Giovane, Cinzia Del; Tedeschi, Federico; Bovo, Chiara; Gastaldon, Chiara; Nosè, Michela; Ogheri, Filippo; Papola, Davide; Purgato, Marianna; Turrini, Giulia; Correll, Christoph U.; Barbui, Corrado

doi:10.1176/appi.ajp.2020.20071120

Cited by 58 publications

(82 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Observational studies might be less restrictive in terms of patient selection and have higher external validity, although an increased risk of detection, performance and prescribing bias may represent a relevant limitation ( 19 ). Although head-to-head comparison of LAIs did not show relevant differences between LAI treatments, aripiprazole, olanzapine, and paliperidone (1- and 3-monthly formulation) might be considered first-line choices, as they are supported by the highest certainty of evidence for both relapse prevention and acceptability ( 20 ). Furthermore, benefits of LAI over oral formulation include improved bioavailability, maintenance stable plasma levels and receptor occupancy avoiding daily peaks, reducing plasma fluctuation, and increasing safety and tolerability, higher relapse prevention, greater compliance and earlier detection of non-adherence, requirement of regular visits with a psychiatrist specialist ( 21 – 23 ).…”

Section: Introductionmentioning

confidence: 99%

The Role of Attitudes Toward Medication and Treatment Adherence in the Clinical Response to LAIs: Findings From the STAR Network Depot Study

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background: Long-acting injectable (LAI) antipsychotics are efficacious in managing psychotic symptoms in people affected by severe mental disorders, such as schizophrenia and bipolar disorder. The present study aimed to investigate whether attitude toward treatment and treatment adherence represent predictors of symptoms changes over time.Methods: The STAR Network “Depot Study” was a naturalistic, multicenter, observational, prospective study that enrolled people initiating a LAI without restrictions on diagnosis, clinical severity or setting. Participants from 32 Italian centers were assessed at three time points: baseline, 6-month, and 12-month follow-up. Psychopathological symptoms, attitude toward medication and treatment adherence were measured using the Brief Psychiatric Rating Scale (BPRS), the Drug Attitude Inventory (DAI-10) and the Kemp's 7-point scale, respectively. Linear mixed-effects models were used to evaluate whether attitude toward medication and treatment adherence independently predicted symptoms changes over time. Analyses were conducted on the overall sample and then stratified according to the baseline severity (BPRS < 41 or BPRS ≥ 41).Results: We included 461 participants of which 276 were males. The majority of participants had received a primary diagnosis of a schizophrenia spectrum disorder (71.80%) and initiated a treatment with a second-generation LAI (69.63%). BPRS, DAI-10, and Kemp's scale scores improved over time. Six linear regressions—conducted considering the outcome and predictors at baseline, 6-month, and 12-month follow-up independently—showed that both DAI-10 and Kemp's scale negatively associated with BPRS scores at the three considered time points. Linear mixed-effects models conducted on the overall sample did not show any significant association between attitude toward medication or treatment adherence and changes in psychiatric symptoms over time. However, after stratification according to baseline severity, we found that both DAI-10 and Kemp's scale negatively predicted changes in BPRS scores at 12-month follow-up regardless of baseline severity. The association at 6-month follow-up was confirmed only in the group with moderate or severe symptoms at baseline.Conclusion: Our findings corroborate the importance of improving the quality of relationship between clinicians and patients. Shared decision making and thorough discussions about benefits and side effects may improve the outcome in patients with severe mental disorders.

show abstract

Section: Introductionmentioning

confidence: 99%

The Role of Attitudes Toward Medication and Treatment Adherence in the Clinical Response to LAIs: Findings From the STAR Network Depot Study

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…A larger study is needed to confirm/replicate our study results. Because a recent network meta‐analysis showed that a 3‐month PP formulation prevented schizophrenia relapse, 7 the effectiveness of this LAI‐AP should be confirmed in clinical practice.…”

Section: Discussionmentioning

confidence: 99%

Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review

Kishi

Sakuma

Okuya

et al. 2021

Neuropsychopharm Rep

View full text Add to dashboard Cite

Aim We conducted a chart review to investigate the detailed outcomes of patients with schizophrenia who discontinued long‐acting injectable second‐generation antipsychotic (LAI‐SGA) therapy due to adverse events (AEs). Methods The study included patients with schizophrenia and related psychotic disorders who commenced LAI‐SGA therapy between January/1//2009 and March/31/2020 at Fujita Health University Hospital in Toyoake, Japan. Results We conducted a chart review of 157 patients with schizophrenia. At the time of this survey, 4 (6.9%), 5 (12.2%), and 10 (17.2%) of the patients in the aripiprazole once monthly, paliperidone palmitate, and risperidone‐LAI groups, respectively, discontinued due to AEs since the start of LAI‐SGA therapy. Three patients required hospitalization for AE treatment. Conclusion The severity of these AEs in most patients is moderate (ie, no hospital treatment required). Due to the small sample size, a larger study is needed to confirm/replicate our study results.

show abstract

“…Los resultados primarios fueron la tasa de recaídas y la interrupción por todas las causas («aceptabilidad»). Los autores concluyen que las formulaciones de LAI de paliperidona (formulación de tres meses), aripiprazol, olanzapina y paliperidona (formulación de un mes) mostraron los tamaños de efecto más altos y la mayor certeza de la evidencia tanto para la prevención de recaídas como para la aceptabilidad 20 .…”

Section: Medicación Inyectableunclassified

Untitled

Escamilla-Orozco¹,

Becerra‐Palars²,

Armendáriz-Vázquez³

et al. 2023

GMM

View full text Add to dashboard Cite

La esquizofrenia es una enfermedad compleja que actualmente no tiene cura. Existen, sin embargo, numerosas terapias que, solas o en combinación, son eficaces para tratar los síntomas de la enfermedad y mantenerla bajo control. La elección del tratamiento debe ser siempre individualizada, y basarse en la presentación clínica de la enfermedad, el estado general del paciente y la eficacia del fármaco, si bien hay que considerar también el costo y el acceso a servicios y al fármaco, que en México tiene algunas limitaciones. Un panel de 12 expertos mexicanos se reunió de forma virtual para revisar los últimos datos publicados y establecer unas recomendaciones de tratamiento en México, basadas en la evidencia, que garanticen una atención médica integral, homogénea, eficiente y con calidad.

show abstract

Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis

Cited by 58 publications

References 104 publications

The Role of Attitudes Toward Medication and Treatment Adherence in the Clinical Response to LAIs: Findings From the STAR Network Depot Study

The Role of Attitudes Toward Medication and Treatment Adherence in the Clinical Response to LAIs: Findings From the STAR Network Depot Study

Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review

Untitled

Contact Info

Product

Resources

About